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Object: Pexelizumab is a humanized monoclonal antibody inhibiting C5 complement.
It has been postulated to improve outcomes in patients undergoing coronary artery by-
pass surgery and urgent reperfusion therapy for ST elevation myocardial infarction.
We aimed at evaluating the risk/benefit profile of pexelizumab (bolus 1 infusion)
versus placebo on top of current approaches in the management of patients with ST
elevation myocardial infarction or undergoing coronary artery bypass.
Methods: We conducted a search of BioMedCentral, CENTRAL, mRCT, and
PubMed without language restrictions (updated October 2007) for randomized con-
trolled trials. Outcomes of interest were the risk of major adverse events (the compos-
ite of all-cause death, myocardial infarction, and thromboembolic stroke), the risk of
single end points, and heart failure.
Results: Seven trials were included (15,196 patients: 7019 patients with ST elevation
myocardial infarction and 8177 undergoing coronary bypass surgery). No benefit of
adding pexelizumab was found in the overall analysis for major adverse events (OR
0.91 [0.76–1.09]; P5 .29], death (OR 0.79 [0.61–1.03], P5 .11], myocardial infarc-
tion (OR 1.04 [0.89–1.22]; P5 .14), stroke (OR 0.95 [0.66–1.38]; P5 .8), heart fail-
ure (OR1.0 [0.82–1.22]; P 5 .99), nor in the settings of patients with ST elevation
myocardial infarction treated with mechanical or pharmacologic reperfusion therapy.
Pexelizumab was associated with a 26% reduction of the risk of death in the setting of
coronary artery bypass (OR 0.74 [0.58–0.94]; P 5 .01). The number needed to treat
was 100.
Conclusion: Our data ruled out the hypothesis of any benefit of adding pexelizumab
on top of currently available therapies for ST elevation myocardial infarction.
However, pexelizumab reduces the risk of death in patients undergoing coronary
artery bypass grafting.
I
schemic heart disease is a major public health problem both in Western and in de-
veloping countries, with 7 million persons in the United States currently affected.1
Despite improvements in diagnosis, pharmacologic therapy, and surgical therapy,
ischemic heart disease remains one of the leading causes of mortality.1 In the past few
years, therapeutic strategies aimed at modifying the role of complement in ischemic
heart disease have received increasing attention. Not only is the complement system
activated by inflammation, but it also plays an integral role in the propagation of in-
flammation, the coagulation cascade, and apoptosis. Once the terminal components of
complement have been activated, they drive the cleavage of C5 into C5a, a powerful
anaphylatoxin and proinflammatory mediator, and C5b, which leads to formation of
C5b-9, the terminal membrane attack complex (MAC). MAC is a transmembrane
channel involved in thrombosis and inflammation, which also causes direct tissue
injury through osmotic lysis.2 Pexelizumab is a recombinant humanized single-chain
monoclonal antibody to C5 that blocks the conversion of C5 to C5a and C5b-9, thus
preventing the formation of MAC. It has been studied in a randomized fashion, in
multiple studies and settings, primarily ST elevation myocardial infarction (STEMI)
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CDAbbreviations and Acronyms
AMI 5 acute myocardial infarction
CABG 5 coronary artery bypass grafting
CHF 5 congestive heart failure
CI 5 confidence interval
MAC 5 membrane attack complex
MAE 5 major adverse event
MI 5 myocardial infarction
OR 5 odds ratio
QUOROM 5 Quality of Reporting of Meta-analyses
STEMI 5 ST elevation myocardial infarction
and on-pump coronary artery bypass grafting (CABG). Our
aim was to provide, by means of systematic review and
meta-analysis, an objective and quantitative evaluation of
the risk/benefit profile of adding pexelizumab to currently
available therapies for patients undergoing urgent reperfu-
sion for STEMI or CABG.
Methods
Study Selection
BioMedCentral, CENTRAL, mRCT, and PubMed were searched
without language restrictions (updated to October 2007), according
to an established method (see appendix for the electronic search
algorithm).3 Pertinent trials were also searched in major recent inter-
national cardiology meetings. References of original and review
articles were cross-checked.
Inclusion/Exclusion Criteria
Specifically, inclusion criteria were (1) randomized allocation, (2)
controlled comparison of pexelizumab (2 mg/kg bolus plus 0.05
mg $ kg21 $ h21 20–24-hour infusion) versus placebo in the setting
of ischemic heart disease, and (3) intention-to-treat analysis. Exclu-
sion criteria were (1) an equivocal treatment allocation process, (2)
significant imbalances in major baseline characteristics among study
groups, and (3) incomplete (,80%) follow-up.
Data Extraction and End Points of Interest
Four trained and independent reviewers (L.T., W.J.V.G., G.B.Z.,
and P.A.) performed data abstraction blindly. Divergences were re-
solved by consensus. The end point of interest was the combined
rate of major adverse events (MAEs), defined as all-cause death,
nonfatal acute myocardial infarction (AMI), or nonfatal thromboem-
bolic stroke. Additional analyses were carried out according to clin-
ical settings, single end points, and the rate of congestive heart
failure (CHF). All data referred to the longest follow-up available
in each trial.
Data Synthesis and Analysis
Review Manager 4.2.54 and SPSS 11.0 (SPSS, Inc, Chicago, Ill)
were used. Review Manager is a comprehensive statistical and
reviewing program, developed and maintained by the Cochrane
Collaboration, which includes ad hoc statistical tools for pooled
estimate calculations, according to several methods.The Journal of ThorStatistical Analyses
Odds ratios with 95% confidence intervals (95% CI) were used as
summary statistics. Binary outcomes from individual studies were
combined with both DerSimonian and Laird5 random-effect model
and fixed-effect model, according to an intention-to-treat analysis.
We also carried out the z test where z 5 estimated effect size/stan-
dard error of the estimated effect size, and the odds ratio (OR) con-
sidered on the log scale. Inasmuch as log(OR) has a unimodal
distribution, the reported z values were analyzed to obtain a 2-tailed
‘‘P,’’ and hypothesis testing results were considered statistically sig-
nificant at the .05 level.6 As per protocol, we calculated the number
needed to treat to prevent an MAE as the inverse of random effect
ORs.
We computed Cochrane Q heterogeneity test (H) by summing
the squared deviations of each study’s estimate from the overall
meta-analytic estimate, weighting each study’s contribution in the
same manner. Heterogeneity was considered significant at ‘‘P for
H’’, .10.6 According to Higgins and associates,7 we used the Q to-
gether with the resulting degrees of freedom (df) to calculate the pro-
portion of variation resulting from heterogeneity: (Inconsistency:
[I2] 5 [Q 2 df]/Q). The degree of inconsistency among studies
(I2) was estimated with scores of less than 25%, between 25% and
75%, and more than 75%, representing, respectively, low, moderate,
or high inconsistency.7 The internal validity of the included trials
was appraised according to the Cochrane Collaboration criteria,
that is, judging the risk of selection, performance, attrition, and
adjudication biases; the risk of bias was expressed as low (A), mod-
erate (B), or high (C); incomplete reporting leading to inability to
ascertain the underlying risk of bias was scored as D. Allocation
concealment was distinguished as adequate (A), unclear (B), inade-
quate (C), or not used (D).6 Sensitivity analysis was performed by
excluding trials one at a time, from those with the lowest to those
with the highest quality score, to assess the contribution of each
study to the pooled estimates.6 The likelihood of publication bias
was assessed graphically by generating a funnel plot for the com-
bined end point of MAEs and mathematically by means of the test
derived by Egger and associates8 (P for significant asymmetry
, 0.1).
This study is inspired by good practice guidelines,9 including
those from the Cochrane Collaboration and the Quality of Reporting
of Meta-analyses (QUOROM) statement.10
Results
Search Results
From 44 potentially relevant citations, our search identified 6
studies that randomized a total of 15,196 patients.11-17 Two
trials investigated the efficacy of pexelizumab as adjunctive
therapy to primary percutaneous intervention in AMI
(STEMI),11,12 3 in the setting of CABG surgery,13-15 1 in
the setting of CABG surgery combined with aortic valve re-
placement,16 and 1 in the setting of patients with AMI treated
with fibrinolysis17 (Figure 1). Four trials11,13,14 randomized
patients to placebo or pexelizumab bolus plus 24-hour infu-
sion and 3 trials12,15-17 to placebo, pexelizumab bolus only,
and pexelizumab bolus plus 24-hour infusion, but we ex-
cluded the bolus-only arms, as per protocol, to avoid further
heterogeneity.acic and Cardiovascular Surgery c Volume 136, Number 4 885
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The main characteristics of the 6 trials are listed in Table 1.
Generally, all studies were of good quality, that is, at low
risk of bias with adequate allocation concealment. One study
has been published only as an abstract presentation.15
Overall Quantitative Findings
The pooled estimates by the random effect model did not dif-
fer significantly from those obtained by the fixed effect
44 potentially relevant citations
identified and screened  for retrieval
7 reports excluded because
post hoc analyses or non
pertinent
30 citations excluded by title or
abstract examination
7 RCTs finally included
14 reports retrieved for detailed
evaluation
Figure 1. Flow diagram according to the QUOROM statement. RCT,
Randomized clinical trial.886 The Journal of Thoracic and Cardiovascular Surgery c Octmodel. The presented results are according to the former.
In the overall analysis, no differences were found between
pexelizumab and placebo for the risk of MAE (OR 0.93
[0.78–1.11], P 5 .29), death (OR 0.79 [0.61–1.03], P 5
.11), myocardial infarction (MI) (OR 1.04 [0.89–1.22],
P 5 .14), stroke (OR 0.95 [0.66–1.38], P 5 .8), or CHF
(OR 1.0 [0.82–1.22], P 5 .98) (Figure 2, Table 2).
Analyses According to Clinical Settings
STEMI. No differences were found between pexelizumab and
placebo in the setting of emergency management of STEMI.
Three trials11,12,17 totaling 7019 patients demonstrated no
benefit with respect to the risk of MAE (OR 0.90 [0.59–
1.36], P 5 .62), death (OR 0.89 [0.57–1.39], P 5 .6), MI
(OR 1.22 [0.9–1.65], P 5 .2), stroke (OR 1.06 [0.69–1.62],
P5 .79%) or CHF (OR 1.03 [0.83–1.27], P5 .8) (Figure 3,
Table 2). Similar results were found in the analysis restricted
to trials enrolling patients undergoing primary percutaneous
coronary intervention (6388 patients). Again, no benefits
were demonstrated with respect to the risks of MAE (OR
0.82 [0.35–1.91], P 5 .64), death (OR 0.73 [0.29–1.87],
P 5 .51), MI (OR 1.28 [0.93–1.76], P 5 .13), stroke (OR
1.18 [0.75–1.86], P 5 .47), or CHF (OR 0.98 [0.78–1.24],
P 5 .89) (Table 2).
CABG surgery. In 4 trials including a total of 8177 pa-
tients,13-16 pexelizumab significantly reduced the relative
risk of all-cause death in patients undergoing CABG surgery
by 26%: (OR 0.74 [0.58–0.94], P 5 .01) with a number
needed to treat of 100 (95% CI 33–167). No differences
were found in the risk of MAE (OR 0.91 [0.74–1.11], P 5
.25), MI (OR 0.98 [0.83–1.15], P 5 .45), stroke (OR 0.75
[0.33–1.70], P 5 .49), or CHF (OR 0.87 [0.53–1.44],
P 5 .6) (Figure 4, Table 2).TABLE 1. Main study characteristics
Trial No.* Clinical Setting
Bolus dosing
(mg/kg)
Infusion dosing
(mg $ kg21 $ h21)
Follow-up
(mo) Primary end point
APEX AMI11 5745 Primary PCI 2 0.05 3 All-cause mortality
COMMA12 552 Primary PCI 2 0.05 6 Infarct size#
PRIMO-CABG13 3099 CABG with or without
valve surgery
2 0.05 3 All-cause mortality or
AMI
Shernan et al14 606 CABG with or without
valve surgery
2 0.05 1 Composite of death,
AMI, severe LVDys,
new CNS deficit
PRIMO-CABG II15 4254 CABG with or without
valve surgery
2 0.05 3 All-cause mortality or
AMI
Carrier et al16 218 CABG with AVR 2 0.05 6 Composite of death and
AMI
COMPLY17 616 Thrombolysis in AMI 2 0.05 6 Infarct size#
*For trial designed with 3 arms (ie, placebo, pexelizumab bolus, and pexelizumab bolus1 24-hour infusion); patients randomized to bolus only were excluded;
#measured by creatine kinase MB area under the curve and peak creatine kinase MB through 72 hours. AMI, Acute myocardial infarction; AVR, aortic valve
replacement; CABG, coronary artery bypass surgery; CNS, central nervous system: LVDys, left ventricular dysfunction; PCI, percutaneous coronary interven-
tion.ober 2008
Testa et al Surgery for Acquired Cardiovascular Disease
A
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are shown by squares and lines. Single study random-effect odds ratios and 95% confidence intervals are shown by
squaresandhorizontal lines.Overall odds ratiowith 95%confidence interval areshownbydiamonds.B,Overall analysis
of the risk of death. C, Overall analysis of the risk of acutemyocardial infarctiion. D, Overall analysis of the risk of throm-
boembolic stroke. E, Overall analysis of the risk of congestive heart failure. OR, Odds ratio; CI, confidence intervals.The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 4 887
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MAE (%) Death (%) AMI (%) Stroke (%) CHF (%)
Pexelizumab Placebo Pexelizumab Placebo Pexelizumab Placebo Pexelizumab Placebo Pexelizumab Placebo
Overall 10.7 10.7 4.1 4.6 5.6 5.5 1.9 2.1 3.8 3.8
STEMI 9.2 8.6 5.2 5.1 2.7 2.2 1.3 1.2 5.1 5.0
CABG 12.0 12.6 3.1 4.2 8.1 7.1 1.8 2.1 1.4 1.6
AMI, Acute myocardial infarction; CABG, coronary artery bypass graft; CHF, congestive heart failure; MAE, major adverse events; STEMI, ST elevation
myocardial infarction.Assessment of Heterogeneity
Significant heterogeneity with moderate/high inconsistency
was found in the analyses for MAE and death both overall
and in the setting of STEMI patients, but not in the setting
of CABG surgery. It is conceivable that such findings reflect
the disparate results of the APEX AMI11 and COMMA12 tri-
als. On sensitivity analysis, the exclusion of any single trial
did not substantively alter the overall results. We also per-
formed a further sensitivity analysis adding one at a time
the bolus-only arms, initially excluded as per protocol, to
minimize inconsistency and heterogeneity. The results did
not significantly differ from the analyses done by excluding
the bolus arms.
Assessment of Possible Biases
The funnel plot for all studies according to the risk of MAE
and death (Figure 5) showed an overall symmetry, further
confirmed by Egger’s test as ‘‘P for asymmetry’’ was
0.985 and 0.844, respectively, thus excluding possible pub-
lication or ‘‘small study’’ bias. Our predefined protocol was
to exclude studies with a follow-up less than 80%; how-
ever, none of the retrieved citations was excluded for this
reason.
Discussion
Inflammation plays a key role in atherosclerosis and plaque
rupture leading to AMI, as well as in microcirculatory dys-
function after ischemia and reperfusion. Complement acti-
vation has a pivotal role in this inflammatory response.
Experimental models of myocardial ischemia and reperfu-
sion have demonstrated that inhibition of the C5 compo-
nent of complement results in reduced infarct size and
less apoptosis.2
In the PRIMO-CABG trial, pexelizumab significantly re-
duced the amount of myocardial damage.13 However, these
results were not reproduced.15 The benefit of adding pexeli-
zumab in the setting of STEMI is also controversial. In the
COMMA trial, pexelizumab resulted in a statistically signif-
icant reduction in mortality but not in a reduction of infarct
size assessed by creatine kinase MB.12 The reduction of in-
flammatory markers, such as high-sensitivity C-reactive pro-
tein and interleukin 6, could explain this puzzling paradox.18888 The Journal of Thoracic and Cardiovascular Surgery c OctHowever, the COMMA trial may represent the play of
chance and have provided an ‘‘optimistic’’ conclusion.12 Al-
though probably underpowered given the low morbidity and
mortality, the APEX-AMI trial was negative, suggesting no
effect of pexelizumab on top of current therapies.11 The
low rate of adverse events in the APEX placebo arm was
not foreseen, so it is conceivable that a treatment benefit
was missed.11
Our systematic review and meta-analysis shows that pex-
elizumab does not provide any clinical benefits in patients un-
dergoing emergency reperfusion therapy for STEMI,
whereas statistically and clinically significant benefits are de-
rived in the setting of CABG as it reduces by almost one third
the relative risk of death, with an estimated number needed to
treat of 100.
The lack of benefit of pexelizumab in the setting of
patients with STEMI contrasts with the apparent benefit
observed in patients undergoing CABG. Such data, despite
promising premises from experimental studies, emphasize
the challenge of translating preliminary data into clinical
practice. Animal models demonstrate increased accumula-
tion of MAC (C5b-9) in reperfusion injury but stable levels
of C5a during cardiopulmonary bypass.19,20 The latter sug-
gests a possible pulmonary vascular sequestration of
C5a-activated granulocyte resulting in the bypass-related
neutropenia.19,20
Upstream delivery of pexelizumab before surgery may
reduce the ‘‘generalized’’ inflammatory process accompany-
ing cardiopulmonary bypass. On the other hand, once micro-
vascular damage and myocardial death owing to necrosis,
‘‘local’’ inflammation, and apoptosis21 have become irrevers-
ible in the setting of STEMI, complement activation is likely
to have progressed to MAC formation, nullifying any benefit
derived from the administration of pexelizumab (Figure 6).
Furthermore, penetration of pexelizumab into myocardial tis-
sue may be limited owing to microvascular obstruction. Met-
abolic and inflammatory derangements have also been
observed during both reperfusion therapy for STEMI and car-
diopulmonary bypass.19,20 However, despite some similari-
ties, the different effect of pexelizumab might reflect the
presence of different activation pathways and/or magnitudes
of activation of the complement cascade.ober 2008
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CDFigure 3. A, Overall analysis of the risk of major adverse events in the setting of STEMI elevation. Single study odds
ratio and 95% confidence intervals are shown by squares and lines. Single study random-effect odds ratios and 95%
confidence intervals are shown by squares and horizontal lines. Overall odds ratio with 95% confidence interval are
shown by diamonds. B, Overall analysis of the risk of death. C, Overall analysis of the risk of acute myocardial in-
farction. D, Overall analysis of the risk of thromboembolic stroke. E, Overall analysis of the risk of congestive heart
failure. OR, Odds ratio; CI, confidence intervals.The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 4 889
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CDFigure 4. A, Overall analysis of the risk of major adverse events in the setting of CABG surgery. Single study odds
ratio and 95% confidence intervals are shown by squares and lines. Single study random-effect odds ratios and 95%
confidence intervals are shown by squares and horizontal lines. Overall odds ratio with 95% confidence interval are
shown by diamonds. B, Overall analysis of the risk of death. C, Overall analysis of the risk of acute myocardial in-
farction. D, Overall analysis of the risk of thromboembolic stroke. E, Overall analysis of the risk of congestive heart
failure. OR, Odds ratio; CI, confidence intervals.890 The Journal of Thoracic and Cardiovascular Surgery c October 2008
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CDFigure 5. Funnel plot analyses according to major
adverse event (A) and death (B). SE, Standard
error; OR, odds ratio.A previous meta-analysis22 suggested a beneficial effect
on 30-day mortality in both clinical settings. Our indepen-
dent, unfunded, and updated analysis differs significantly
from the previous study in several ways. First, we did not in-
clude the bolus-only arms in the primary analysis, inasmuch
as our sensitivity analysis demonstrated both increased het-
erogeneity and inconsistency by including this group. We in-
cluded all the available data on the topic, assessing not only
the risk of overall death but also that of otherMAEs, including
stroke and congestive heart failure. We performed a pre-spec-
ified analysis according to different clinical settings, showing
an unexpected discrepancy in the usefulness of pexelizumab
in patients with STEMI compared with those undergoing
CABG. The reason that our findings differ from those of
the previous study might be due to the addition of two large
recent trials not included in the previous analysis.11,15
A limitation inherent to all meta-analyses is the potential
heterogeneity among studies, in terms of protocols (eg, con-
trol treatments and length of follow-up), patients, and/or sam-The Journal of Thople sizes. Such diversity may lead to inaccurate conclusions.
However, both the Cochrane Q heterogeneity test (which
assesses heterogeneity among ORs and the validity of pool-
ing the results) and the test of inconsistency (I2) indicated sig-
nificant heterogeneity and inconsistency only for the overall
analyses of MAE and death, possibly consistent with the di-
versity between trials evaluating pexelizumab in the STEMI
or CABG setting. Moreover, the overall quality of included
trials was good, thus confirming the robustness of the present
meta-analysis.
Conclusion
The rationale and potential benefits of adding a C5 comple-
ment inhibitor to currently available therapy for STEMI
and CABG surgery are attractive. Unfortunately, there ap-
pears to be no improvement in outcomes for patients under-
going reperfusion for STEMI. Alternatively, the benefit in
patients undergoing on-pump CABG appears real and
impressive, with a significant reduction in death.racic and Cardiovascular Surgery c Volume 136, Number 4 891
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CDFigure 6. Complement is a highly conserved
innate immune cascade of several proteins in-
teracting to recognize and destroy pathogens.
According to the nature of the pathogen and/or
the activating surface, three different activa-
tion pathways are known: classical, alterna-
tive, and lectin. The classical pathway is
activated by the interaction of C1q with anti-
body–antigen complexes, but also with nonim-
mune molecules. The alternative pathway is
activated by activating surfaces in the ab-
sence of immune complexes and leads to the
deposition of C3 fragments on the target cells.
The lectin pathway is activated by binding of
mannan-binding lectin to carbohydrates ex-
pressed on pathogens but not on "self'' cells.
The common end result of these pathways is
either the opsonization or the destruction
(through formation of the lytic molecule C5b-
9, the membrane attack complex) of the target
pathogen. The system is regulated by proteins
such as fI, DAF, CR1, MCP. During cardiopulmo-
nary bypass, the complement system is mainly
activated by the alternative pathways. This
leads to the generalized inflammatory process
accompanying the bypass. Upstream delivery
of pexelizumab might be efficacious as it in-
hibits the formation of MAC at an early stage,
and also of C5a, a potent anaphylotoxin. In
the STEMI setting the late delivery of pexelizu-
mab, once the microvascular damage and
myocardial death have become irreversible,
might be ineffective as the MAC and C5a for-
mation have been completed. Moreover, the
microvascular disfunction can also limit the
penetration of pexelizumab into the perinfarct
area, where a localized inflammatory/apopto-
tic process is present. C, Complement compo-
nent; DAF, decay accelerating factor; MAC,
membrane attack complex; MASP, MBL-asso-
ciated serine proteinase; MBL, mannan-bind-
ing lectin; MCP, membrane cofactor protein;
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